ID   NLK_HUMAN               Reviewed;         527 AA.
AC   Q9UBE8; B2RCX1; Q2PNI9; Q6P2A3;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   03-NOV-2009, sequence version 2.
DT   12-OCT-2022, entry version 194.
DE   RecName: Full=Serine/threonine-protein kinase NLK;
DE            EC=2.7.11.24;
DE   AltName: Full=Nemo-like kinase;
DE   AltName: Full=Protein LAK1;
GN   Name=NLK; Synonyms=LAK1 {ECO:0000312|EMBL:AAD56013.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000312|EMBL:AAF04857.1}
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta {ECO:0000269|PubMed:10863097};
RX   PubMed=10863097; DOI=10.1016/s0378-1119(00)00188-8;
RA   Kehrer-Sawatzki H., Moschgath E., Maier C., Legius E., Elgar G., Krone W.;
RT   "Characterization of the Fugu rubripes NLK and FN5 genes flanking the NF1
RT   (Neurofibromatosis type 1) gene in the 5' direction and mapping of the
RT   human counterparts.";
RL   Gene 251:63-71(2000).
RN   [2] {ECO:0000312|EMBL:AAD56013.1}
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=T-cell;
RA   Wang C., Lo H.;
RT   "Cloning of human LAK1 cDNA.";
RL   Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4] {ECO:0000312|EMBL:AAD56013.1}
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=12482967; DOI=10.1128/mcb.23.1.131-139.2003;
RA   Ishitani T., Kishida S., Hyodo-Miura J., Ueno N., Yasuda J., Waterman M.,
RA   Shibuya H., Moon R.T., Ninomiya-Tsuji J., Matsumoto K.;
RT   "The TAK1-NLK mitogen-activated protein kinase cascade functions in the
RT   Wnt-5a/Ca(2+) pathway to antagonize Wnt/beta-catenin signaling.";
RL   Mol. Cell. Biol. 23:131-139(2003).
RN   [7]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=15004007; DOI=10.1101/gad.1166904;
RA   Ohkawara B., Shirakabe K., Hyodo-Miura J., Matsuo R., Ueno N.,
RA   Matsumoto K., Shibuya H.;
RT   "Role of the TAK1-NLK-STAT3 pathway in TGF-beta-mediated mesoderm
RT   induction.";
RL   Genes Dev. 18:381-386(2004).
RN   [8] {ECO:0000305}
RP   INTERACTION WITH MYB AND HIPK2.
RX   PubMed=15082531; DOI=10.1101/gad.1170604;
RA   Kanei-Ishii C., Ninomiya-Tsuji J., Tanikawa J., Nomura T., Ishitani T.,
RA   Kishida S., Kokura K., Kurahashi T., Ichikawa-Iwata E., Kim Y.,
RA   Matsumoto K., Ishii S.;
RT   "Wnt-1 signal induces phosphorylation and degradation of c-Myb protein via
RT   TAK1, HIPK2, and NLK.";
RL   Genes Dev. 18:816-829(2004).
RN   [9]
RP   FUNCTION.
RX   PubMed=14960582; DOI=10.1074/jbc.m307801200;
RA   Smit L., Baas A., Kuipers J., Korswagen H., van de Wetering M., Clevers H.;
RT   "Wnt activates the Tak1/Nemo-like kinase pathway.";
RL   J. Biol. Chem. 279:17232-17240(2004).
RN   [10]
RP   FUNCTION, AUTOPHOSPHORYLATION, INTERACTION WITH MAP3K7 AND STAT3, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=15764709; DOI=10.1073/pnas.0500679102;
RA   Kojima H., Sasaki T., Ishitani T., Iemura S., Zhao H., Kaneko S.,
RA   Kunimoto H., Natsume T., Matsumoto K., Nakajima K.;
RT   "STAT3 regulates Nemo-like kinase by mediating its interaction with IL-6-
RT   stimulated TGFbeta-activated kinase 1 for STAT3 Ser-727 phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:4524-4529(2005).
RN   [11]
RP   INTERACTION WITH RNF138 AND TCF7L2.
RX   PubMed=16714285; DOI=10.1074/jbc.m602089200;
RA   Yamada M., Ohnishi J., Ohkawara B., Iemura S., Satoh K., Hyodo-Miura J.,
RA   Kawachi K., Natsume T., Shibuya H.;
RT   "NARF, an nemo-like kinase (NLK)-associated ring finger protein regulates
RT   the ubiquitylation and degradation of T cell factor/lymphoid enhancer
RT   factor (TCF/LEF).";
RL   J. Biol. Chem. 281:20749-20760(2006).
RN   [12]
RP   RETRACTED PAPER.
RX   PubMed=17952062; DOI=10.1038/ncb1647;
RA   Takada I., Mihara M., Suzawa M., Ohtake F., Kobayashi S., Igarashi M.,
RA   Youn M.Y., Takeyama K., Nakamura T., Mezaki Y., Takezawa S., Yogiashi Y.,
RA   Kitagawa H., Yamada G., Takada S., Minami Y., Shibuya H., Matsumoto K.,
RA   Kato S.;
RT   "A histone lysine methyltransferase activated by non-canonical Wnt
RT   signalling suppresses PPAR-gamma transactivation.";
RL   Nat. Cell Biol. 9:1273-1285(2007).
RN   [13]
RP   RETRACTION NOTICE OF PUBMED:17952062.
RX   PubMed=25358353; DOI=10.1038/ncb3069;
RA   Takada I., Mihara M., Suzawa M., Ohtake F., Kobayashi S., Igarashi M.,
RA   Youn M.Y., Takeyama K., Nakamura T., Mezaki Y., Takezawa S., Yogiashi Y.,
RA   Kitagawa H., Yamada G., Takada S., Minami Y., Shibuya H., Matsumoto K.,
RA   Kato S.;
RL   Nat. Cell Biol. 16:1126-1126(2014).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-298 AND SER-522, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-298, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   FUNCTION, INTERACTION WITH FOXO1, AND MUTAGENESIS OF LYS-167.
RX   PubMed=20061393; DOI=10.1074/jbc.m110.101824;
RA   Kim S., Kim Y., Lee J., Chung J.;
RT   "Regulation of FOXO1 by TAK1-Nemo-like kinase pathway.";
RL   J. Biol. Chem. 285:8122-8129(2010).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH NOTCH1.
RX   PubMed=20118921; DOI=10.1038/ncb2028;
RA   Ishitani T., Hirao T., Suzuki M., Isoda M., Ishitani S., Harigaya K.,
RA   Kitagawa M., Matsumoto K., Itoh M.;
RT   "Nemo-like kinase suppresses Notch signalling by interfering with formation
RT   of the Notch active transcriptional complex.";
RL   Nat. Cell Biol. 12:278-285(2010).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH FOXO1; FOXO3 AND FOXO4.
RX   PubMed=20874444; DOI=10.1089/ars.2010.3243;
RA   Szypowska A.A., de Ruiter H., Meijer L.A.T., Smits L.M.M.,
RA   Burgering B.M.T.;
RT   "Oxidative stress-dependent regulation of Forkhead box O4 activity by nemo-
RT   like kinase.";
RL   Antioxid. Redox Signal. 14:563-578(2011).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH DAPK3 AND TCF7L2.
RX   PubMed=21454679; DOI=10.1074/jbc.m110.189829;
RA   Togi S., Ikeda O., Kamitani S., Nakasuji M., Sekine Y., Muromoto R.,
RA   Nanbo A., Oritani K., Kawai T., Akira S., Matsuda T.;
RT   "Zipper-interacting protein kinase (ZIPK) modulates canonical Wnt/beta-
RT   catenin signaling through interaction with Nemo-like kinase and T-cell
RT   factor 4 (NLK/TCF4).";
RL   J. Biol. Chem. 286:19170-19177(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-298, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH ATF5.
RX   PubMed=25512613; DOI=10.1128/mcb.01228-14;
RA   Zhang Z.Y., Li S.Z., Zhang H.H., Wu Q.R., Gong J., Liang T., Gao L.,
RA   Xing N.N., Liu W.B., Du R.L., Zhang X.D.;
RT   "Stabilization of ATF5 by TAK1-Nemo-like kinase critically regulates the
RT   interleukin-1beta-stimulated C/EBP signaling pathway.";
RL   Mol. Cell. Biol. 35:778-788(2015).
RN   [22]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-343.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that regulates a number of
CC       transcription factors with key roles in cell fate determination.
CC       Positive effector of the non-canonical Wnt signaling pathway, acting
CC       downstream of WNT5A, MAP3K7/TAK1 and HIPK2. Negative regulator of the
CC       canonical Wnt/beta-catenin signaling pathway. Binds to and
CC       phosphorylates TCF7L2/TCF4 and LEF1, promoting the dissociation of the
CC       TCF7L2/LEF1/beta-catenin complex from DNA, as well as the
CC       ubiquitination and subsequent proteolysis of LEF1. Together these
CC       effects inhibit the transcriptional activation of canonical Wnt/beta-
CC       catenin target genes. Negative regulator of the Notch signaling
CC       pathway. Binds to and phosphorylates NOTCH1, thereby preventing the
CC       formation of a transcriptionally active ternary complex of NOTCH1,
CC       RBPJ/RBPSUH and MAML1. Negative regulator of the MYB family of
CC       transcription factors. Phosphorylation of MYB leads to its subsequent
CC       proteolysis while phosphorylation of MYBL1 and MYBL2 inhibits their
CC       interaction with the coactivator CREBBP. Other transcription factors
CC       may also be inhibited by direct phosphorylation of CREBBP itself. Acts
CC       downstream of IL6 and MAP3K7/TAK1 to phosphorylate STAT3, which is in
CC       turn required for activation of NLK by MAP3K7/TAK1. Upon IL1B stimulus,
CC       cooperates with ATF5 to activate the transactivation activity of C/EBP
CC       subfamily members. Phosphorylates ATF5 but also stabilizes ATF5 protein
CC       levels in a kinase-independent manner (PubMed:25512613).
CC       {ECO:0000250|UniProtKB:O54949, ECO:0000269|PubMed:12482967,
CC       ECO:0000269|PubMed:14960582, ECO:0000269|PubMed:15004007,
CC       ECO:0000269|PubMed:15764709, ECO:0000269|PubMed:20061393,
CC       ECO:0000269|PubMed:20118921, ECO:0000269|PubMed:20874444,
CC       ECO:0000269|PubMed:21454679, ECO:0000269|PubMed:25512613}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.24;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Activated by dimerization and subsequent
CC       intermolecular autophosphorylation on Thr-298 (By similarity).
CC       Activated by the non-canonical Wnt signaling pathway, in which WNT5A
CC       treatment leads to activation of MAP3K7/TAK1 and HIPK2, which
CC       subsequently phosphorylates and activates this protein. Other cytokines
CC       such as IL6 may also activate this regulatory circuit. {ECO:0000250,
CC       ECO:0000269|PubMed:12482967, ECO:0000269|PubMed:15004007}.
CC   -!- SUBUNIT: Homodimer. Homodimerization is required for intermolecular
CC       autophosphorylation, kinase activation and nuclear localization (By
CC       similarity). May interact with components of cullin-RING-based SCF
CC       (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complexes (By
CC       similarity). Interacts with LEF1, MEF2A, MYBL1 and MYBL2 (By
CC       similarity). Interacts with the upstream activating kinases HIPK2 and
CC       MAP3K7/TAK1. Interaction with MAP3K7/TAK1 seems to be indirect, and may
CC       be mediated by other proteins such as STAT3, TAB1 and TAB2. Interacts
CC       with and phosphorylates a number of transcription factors including
CC       FOXO1, FOXO3, FOXO4, MYB, NOTCH1 and TCF7L2/TCF4. Interacts with
CC       DAPK3/ZIPK, and this interaction may disrupt interaction with
CC       transcription factors such as TCF7L2/TCF4. Interacts with RNF138/NARF.
CC       Interacts with ATF5; the interaction stabilizes ATF5 at the protein
CC       level in a kinase-independent manner (PubMed:25512613). {ECO:0000250,
CC       ECO:0000269|PubMed:15082531, ECO:0000269|PubMed:15764709,
CC       ECO:0000269|PubMed:16714285, ECO:0000269|PubMed:20061393,
CC       ECO:0000269|PubMed:20118921, ECO:0000269|PubMed:20874444,
CC       ECO:0000269|PubMed:21454679, ECO:0000269|PubMed:25512613}.
CC   -!- INTERACTION:
CC       Q9UBE8; P54253: ATXN1; NbExp=4; IntAct=EBI-366978, EBI-930964;
CC       Q9UBE8; O43293: DAPK3; NbExp=3; IntAct=EBI-366978, EBI-77293;
CC       Q9UBE8; P28799: GRN; NbExp=7; IntAct=EBI-366978, EBI-747754;
CC       Q9UBE8; P42858: HTT; NbExp=3; IntAct=EBI-366978, EBI-466029;
CC       Q9UBE8; Q9BYR5: KRTAP4-2; NbExp=3; IntAct=EBI-366978, EBI-10172511;
CC       Q9UBE8; Q6L8G9: KRTAP5-6; NbExp=3; IntAct=EBI-366978, EBI-10250562;
CC       Q9UBE8; P26371: KRTAP5-9; NbExp=3; IntAct=EBI-366978, EBI-3958099;
CC       Q9UBE8; Q9UHB4: NDOR1; NbExp=3; IntAct=EBI-366978, EBI-10249760;
CC       Q9UBE8; Q2TAL8: QRICH1; NbExp=3; IntAct=EBI-366978, EBI-2798044;
CC       Q9UBE8; Q96PM5: RCHY1; NbExp=5; IntAct=EBI-366978, EBI-947779;
CC       Q9UBE8; Q13485: SMAD4; NbExp=6; IntAct=EBI-366978, EBI-347263;
CC       Q9UBE8; Q14186: TFDP1; NbExp=2; IntAct=EBI-366978, EBI-749713;
CC       Q9UBE8; Q9H4I2: ZHX3; NbExp=4; IntAct=EBI-366978, EBI-948582;
CC       Q9UBE8; Q9H4I2-2: ZHX3; NbExp=3; IntAct=EBI-366978, EBI-10693326;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}. Cytoplasm {ECO:0000250}.
CC       Note=Predominantly nuclear. A smaller fraction is cytoplasmic (By
CC       similarity). {ECO:0000250}.
CC   -!- DOMAIN: Contains a TQE activation loop motif in which
CC       autophosphorylation of the threonine residue (Thr-298) is sufficient
CC       for kinase activation. This mode of activation contrasts with that of
CC       classical MAP kinases, which contain a TXY activation loop motif in
CC       which phosphorylation of both the threonine and tyrosine residues is
CC       required for kinase activation.
CC   -!- PTM: Phosphorylated on Thr-298. Intermolecular autophosphorylation on
CC       Thr-298 activates the enzyme.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. MAP kinase subfamily. {ECO:0000305}.
CC   -!- CAUTION: Was reported to form a transcriptional repressor complex with
CC       CHD7 and SETDB1 involved in PPARG repression (PubMed:17952062).
CC       However, this work was later retracted (PubMed:25358353).
CC       {ECO:0000269|PubMed:17952062, ECO:0000269|PubMed:25358353}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD56013.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAF04857.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=ABC40748.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAG37718.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF197898; AAF04857.1; ALT_INIT; mRNA.
DR   EMBL; AF180819; AAD56013.1; ALT_INIT; mRNA.
DR   EMBL; AK315315; BAG37718.1; ALT_INIT; mRNA.
DR   EMBL; DQ316259; ABC40748.1; ALT_INIT; Genomic_DNA.
DR   EMBL; BC064663; AAH64663.2; -; mRNA.
DR   CCDS; CCDS11224.2; -.
DR   RefSeq; NP_057315.3; NM_016231.4.
DR   AlphaFoldDB; Q9UBE8; -.
DR   SMR; Q9UBE8; -.
DR   BioGRID; 119685; 64.
DR   CORUM; Q9UBE8; -.
DR   IntAct; Q9UBE8; 41.
DR   MINT; Q9UBE8; -.
DR   STRING; 9606.ENSP00000384625; -.
DR   BindingDB; Q9UBE8; -.
DR   ChEMBL; CHEMBL5364; -.
DR   DrugCentral; Q9UBE8; -.
DR   GuidetoPHARMACOLOGY; 2125; -.
DR   iPTMnet; Q9UBE8; -.
DR   PhosphoSitePlus; Q9UBE8; -.
DR   BioMuta; NLK; -.
DR   DMDM; 262527551; -.
DR   EPD; Q9UBE8; -.
DR   jPOST; Q9UBE8; -.
DR   MassIVE; Q9UBE8; -.
DR   PaxDb; Q9UBE8; -.
DR   PeptideAtlas; Q9UBE8; -.
DR   PRIDE; Q9UBE8; -.
DR   ProteomicsDB; 83953; -.
DR   Antibodypedia; 13947; 388 antibodies from 36 providers.
DR   DNASU; 51701; -.
DR   Ensembl; ENST00000407008.8; ENSP00000384625.3; ENSG00000087095.13.
DR   GeneID; 51701; -.
DR   KEGG; hsa:51701; -.
DR   MANE-Select; ENST00000407008.8; ENSP00000384625.3; NM_016231.5; NP_057315.3.
DR   UCSC; uc010crj.4; human.
DR   CTD; 51701; -.
DR   DisGeNET; 51701; -.
DR   GeneCards; NLK; -.
DR   HGNC; HGNC:29858; NLK.
DR   HPA; ENSG00000087095; Tissue enhanced (retina).
DR   MIM; 609476; gene.
DR   neXtProt; NX_Q9UBE8; -.
DR   OpenTargets; ENSG00000087095; -.
DR   PharmGKB; PA134914500; -.
DR   VEuPathDB; HostDB:ENSG00000087095; -.
DR   eggNOG; KOG0664; Eukaryota.
DR   GeneTree; ENSGT00940000158363; -.
DR   InParanoid; Q9UBE8; -.
DR   OMA; HSCMCRC; -.
DR   OrthoDB; 741207at2759; -.
DR   PhylomeDB; Q9UBE8; -.
DR   TreeFam; TF315210; -.
DR   PathwayCommons; Q9UBE8; -.
DR   Reactome; R-HSA-4086398; Ca2+ pathway.
DR   SignaLink; Q9UBE8; -.
DR   SIGNOR; Q9UBE8; -.
DR   BioGRID-ORCS; 51701; 17 hits in 1114 CRISPR screens.
DR   ChiTaRS; NLK; human.
DR   GeneWiki; NLK; -.
DR   GenomeRNAi; 51701; -.
DR   Pharos; Q9UBE8; Tchem.
DR   PRO; PR:Q9UBE8; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q9UBE8; protein.
DR   Bgee; ENSG00000087095; Expressed in middle temporal gyrus and 187 other tissues.
DR   ExpressionAtlas; Q9UBE8; baseline and differential.
DR   Genevisible; Q9UBE8; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; ISS:UniProtKB.
DR   GO; GO:0004707; F:MAP kinase activity; ISS:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0042169; F:SH2 domain binding; ISS:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; ISS:UniProtKB.
DR   GO; GO:0030178; P:negative regulation of Wnt signaling pathway; ISS:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; ISS:UniProtKB.
DR   GO; GO:0042501; P:serine phosphorylation of STAT protein; ISS:UniProtKB.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007223; P:Wnt signaling pathway, calcium modulating pathway; TAS:Reactome.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cytoplasm; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transcription; Transcription regulation;
KW   Transferase; Wnt signaling pathway.
FT   CHAIN           1..527
FT                   /note="Serine/threonine-protein kinase NLK"
FT                   /id="PRO_0000186336"
FT   DOMAIN          138..427
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..304
FT                   /note="Required for interaction with TAB2"
FT                   /evidence="ECO:0000250"
FT   REGION          1..125
FT                   /note="Sufficient for interaction with DAPK3"
FT                   /evidence="ECO:0000269|PubMed:21454679"
FT   REGION          22..72
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          90..140
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          124..416
FT                   /note="Sufficient for interaction with DAPK3"
FT                   /evidence="ECO:0000269|PubMed:21454679"
FT   REGION          428..527
FT                   /note="Required for homodimerization and kinase activation
FT                   and localization to the nucleus"
FT                   /evidence="ECO:0000250"
FT   REGION          434..527
FT                   /note="Required for interaction with TAB2"
FT                   /evidence="ECO:0000250"
FT   MOTIF           298..300
FT                   /note="TQE"
FT   COMPBIAS        25..53
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        264
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         144..152
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         167
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         298
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         522
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   VARIANT         177
FT                   /note="V -> A (in dbSNP:rs11871287)"
FT                   /id="VAR_019549"
FT   VARIANT         343
FT                   /note="A -> T (in a glioblastoma multiforme sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042273"
FT   MUTAGEN         167
FT                   /note="K->N: Abrogates kinase activity."
FT                   /evidence="ECO:0000269|PubMed:20061393"
FT   CONFLICT        25
FT                   /note="A -> T (in Ref. 5; AAH64663)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   527 AA;  58283 MW;  CE6AEBA7D8133989 CRC64;
     MSLCGARANA KMMAAYNGGT SAAAAGHHHH HHHHLPHLPP PHLHHHHHPQ HHLHPGSAAA
     VHPVQQHTSS AAAAAAAAAA AAAMLNPGQQ QPYFPSPAPG QAPGPAAAAP AQVQAAAAAT
     VKAHHHQHSH HPQQQLDIEP DRPIGYGAFG VVWSVTDPRD GKRVALKKMP NVFQNLVSCK
     RVFRELKMLC FFKHDNVLSA LDILQPPHID YFEEIYVVTE LMQSDLHKII VSPQPLSSDH
     VKVFLYQILR GLKYLHSAGI LHRDIKPGNL LVNSNCVLKI CDFGLARVEE LDESRHMTQE
     VVTQYYRAPE ILMGSRHYSN AIDIWSVGCI FAELLGRRIL FQAQSPIQQL DLITDLLGTP
     SLEAMRTACE GAKAHILRGP HKQPSLPVLY TLSSQATHEA VHLLCRMLVF DPSKRISAKD
     ALAHPYLDEG RLRYHTCMCK CCFSTSTGRV YTSDFEPVTN PKFDDTFEKN LSSVRQVKEI
     IHQFILEQQK GNRVPLCINP QSAAFKSFIS STVAQPSEMP PSPLVWE
//
